Literature DB >> 20441998

Usage of heparan sulfate, integrins, and FAK in HPV16 infection.

Cynthia Y Abban1, Patricio I Meneses.   

Abstract

Human papillomavirus type 16 (HPV16) is the major causative agent of cervical cancer. Studies regarding the early binding and signaling molecules that play a significant role in infection are still lacking. The current study analyzes the role of heparan sulfate, integrins, and the signaling molecule FAK in HPV16 infection of human adult keratinocytes cell line (HaCaTs). Our data demonstrate that infection requires the binding of viral particles to heparan sulfate followed by activation of focal adhesion kinase through an integrin. Infections were reduced in the presence of the FAK inhibitor, TAE226. TAE226 was observed to inhibit viral entry to the early endosome a known infectious route. These findings suggest that FAK can serve as a novel target for antiviral therapy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441998      PMCID: PMC2883642          DOI: 10.1016/j.virol.2010.04.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  51 in total

1.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 2.  Focal adhesion kinase: the first ten years.

Authors:  J Thomas Parsons
Journal:  J Cell Sci       Date:  2003-04-15       Impact factor: 5.285

3.  Human papillomavirus infection requires cell surface heparan sulfate.

Authors:  T Giroglou; L Florin; F Schäfer; R E Streeck; M Sapp
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 4.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

5.  Papillomaviruses infect cells via a clathrin-dependent pathway.

Authors:  Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2003-03-01       Impact factor: 3.616

6.  Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells.

Authors:  Latifa Bousarghin; Antoine Touzé; Pierre-Yves Sizaret; Pierre Coursaget
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Martin Sapp
Journal:  Virology       Date:  2002-08-01       Impact factor: 3.616

8.  Activation of focal adhesion kinase in adenovirus-infected human corneal fibroblasts.

Authors:  Kanchana Natarajan; Abboud J Ghalayini; Robert S Sterling; Robert M Holbrook; Ronald C Kennedy; James Chodosh
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-08       Impact factor: 4.799

9.  Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity.

Authors:  Pramod P Naranatt; Shaw M Akula; Christopher A Zien; Harinivas H Krishnan; Bala Chandran
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  The role of NH4Cl and cysteine proteases in Human Papillomavirus type 16 infection.

Authors:  Sarah A Dabydeen; Patricio I Meneses
Journal:  Virol J       Date:  2009-07-20       Impact factor: 4.099

View more
  48 in total

Review 1.  The evolving field of human papillomavirus receptor research: a review of binding and entry.

Authors:  Adam B Raff; Andrew W Woodham; Laura M Raff; Joseph G Skeate; Lisa Yan; Diane M Da Silva; Mario Schelhaas; W Martin Kast
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 2.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

Review 3.  Cruising the cellular highways: How human papillomavirus travels from the surface to the nucleus.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G Guion; Martin Sapp
Journal:  Virus Res       Date:  2016-10-29       Impact factor: 3.303

4.  Incoming human papillomavirus type 16 genome resides in a vesicular compartment throughout mitosis.

Authors:  Stephen DiGiuseppe; Wioleta Luszczek; Timothy R Keiffer; Malgorzata Bienkowska-Haba; Lucile G M Guion; Martin J Sapp
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-17       Impact factor: 11.205

5.  HPV16 infection of HaCaTs is dependent on β4 integrin, and α6 integrin processing.

Authors:  Pınar Aksoy; Cynthia Y Abban; Elizabeth Kiyashka; Weitao Qiang; Patricio I Meneses
Journal:  Virology       Date:  2013-11-25       Impact factor: 3.616

6.  A Dual Role for the Nonreceptor Tyrosine Kinase Pyk2 during the Intracellular Trafficking of Human Papillomavirus 16.

Authors:  Elinor Y Gottschalk; Patricio I Meneses
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

Review 7.  Concepts of papillomavirus entry into host cells.

Authors:  Patricia M Day; Mario Schelhaas
Journal:  Curr Opin Virol       Date:  2013-12-14       Impact factor: 7.090

8.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

9.  Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.

Authors:  Zurab Surviladze; Rosa T Sterk; Sergio A DeHaro; Michelle A Ozbun
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16.

Authors:  Kathleen F Richards; Malgorzata Bienkowska-Haba; Jhimli Dasgupta; Xiaojiang S Chen; Martin Sapp
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.